Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcers
March 3rd, 2023
The present protocol describes a prospective, randomized, controlled clinical study that evaluates a human umbilical cord mesenchymal stem cell injection for the treatment of chronic diabetic foot ulcers.
Our protocol aim to provide a uniform model for system cells injection to treat diabetic ulcers to evaluate the safety and effectiveness of this treatment. We provide a research standard for stem cells for treating diabetic ulcer, which has the advantages of the high consistencies and the repeatability. Diabetic ulcer is just one of the representative of common refractory ulcer.
We hope to apply stem cells to the treatment of other ulcers or other diseases through this protocol. When using this method to treat the body ulcers, it is necessary to ensure the safety of the source of stem cells and to monitor whether patients experience immune rejection. Through visual demonstration, we hope to provide standard and references for other researchers in the treatment of diabetic ulcers or other refractory wounds.
Begin by disinfecting the wound site with povidone iodine solution. Remove any necrotic tissue using surgical scissors. Now use the syringe to aspirate 50 milliliters of saline to clean the wound surface.
Measure the wound area using the sterile foil edge hook method. Apply the sterile film transparent dressing to the wound surface. Outline the shape of the wound surface with a marker to calculate the wound area.
In the stem cell therapy group, inject the human umbilical cord mesenchymal stem cells into the wound periphery and base. Cover the wound surface with an appropriately sized sterile dressing and then bandage it. In the conventional wound treatment group, once the site has been cleaned, measured, and marked as described earlier, cover the wound with a silver ion dressing before bandaging it.
The wounds treated with the human umbilical cord mesenchymal stem cells reduced in size from 3.5 square centimeters to 2.6 square centimeters on the eighth day. By the 15th day, the wound size was 1.8 square centimeters. It was further reduced to 1.25 square centimeters on the 22nd day post-treatment.
The wounds treated with a conventional silver ion dressing also decreased in size from 1.25 square centimeters to 0.875 square centimeters on the eighth day. By the 15th day, the wound size was 0.8 square centimeters. A slight reduction to 0.75 square centimeters was seen by the 22nd day.
The critical step of this experiment is to inject stem cells into the wound at a fixed point and a fixed time. Moreover, long-term followup is required for laboratory tests. According to the biological characteristics of stem cells, following this procedure, it can be applied to burn wounds, infection wounds, and et cetera, which plays an important role in the research of wound healing.
After the development of stem cells technology for treating diabetic ulcers, we believe it can play a huge role in most wound treatment through its ability to secrete growth factors and vasoactive factors effectively.
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol outlines a randomized, controlled clinical study assessing the efficacy of human umbilical cord mesenchymal stem cell injections for chronic diabetic foot ulcers. The aim is to establish a standardized approach for stem cell treatment of diabetic ulcers.
Key Study Components
Area of Science
- Stem Cell Therapy
- Diabetic Ulcers
- Clinical Research
Background
- Diabetic ulcers are common and often refractory to treatment.
- Stem cells have potential therapeutic benefits for wound healing.
- Safety and effectiveness of stem cell injections need thorough evaluation.
- Standardized protocols can enhance research consistency.
Purpose of Study
- To evaluate the safety of umbilical cord mesenchymal stem cells.
- To assess the effectiveness of this treatment for diabetic foot ulcers.
- To provide a research standard for future studies on ulcer treatments.
Methods Used
- Randomized controlled trial design.
- Injection of human umbilical cord mesenchymal stem cells.
- Monitoring of patient safety and immune response.
- Visual demonstrations to standardize procedures.
Main Results
- Evaluation of treatment safety and patient outcomes.
- Assessment of immune rejection incidents.
- Standardization of stem cell injection protocols.
- Potential applicability to other types of ulcers.
Conclusions
- Human umbilical cord mesenchymal stem cells show promise for treating diabetic ulcers.
- Standardized protocols can aid in future research.
- Further studies are needed to explore broader applications.
Frequently Asked Questions
Executive Industry Relevance
Standardized protocols for human umbilical cord mesenchymal stem cell injections address a critical need for reproducible, scalable interventions in refractory diabetic foot ulcers. This approach enables consistent evaluation of safety and efficacy, supporting predictive confidence at the intersection of regenerative medicine and wound healing. The protocol's uniformity facilitates cross-study comparability and informs risk-adjusted advancement decisions in early translational pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables systematic interrogation of stem cell-mediated wound healing mechanisms.
- Supports biological de-risking by standardizing cell source and injection parameters.
- Facilitates functional validation of regenerative targets in chronic ulcer models.
Screening & Assay Development
- Establishes reproducible wound measurement and monitoring workflows for quantitative assessment.
- Provides a validated system for comparing stem cell and conventional treatments.
- Enables assay standardization for downstream screening of adjunctive therapies.
Translational & Preclinical Research
- Aligns with disease-relevant models for diabetic wound healing.
- Supports continuity from discovery through preclinical validation of cell-based therapies.
- Informs risk-adjusted decisions for advancing regenerative candidates.
Pipeline & Workflow Integration
This protocol integrates into the discovery-to-preclinical continuum by providing a standardized model for evaluating cell-based interventions in chronic wounds.
- Discovery Biology: Supports hypothesis testing on stem cell efficacy and mechanism in wound repair.
- Screening: Delivers reproducible, quantitative wound size measurements for comparative analysis.
- Analytics: Enables statistical evaluation of wound closure rates and immune response monitoring.
- Translational Research: Bridges discovery findings to preclinical validation in disease-relevant ulcer models.
- Enterprise Reuse: Offers a referenceable protocol adaptable to other refractory wound indications.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in regenerative target validation and wound healing outcomes.
- Operational Value: Promotes standardization, reproducibility, and scalability across research teams.
- Strategic Value: Enables informed go/no-go decisions and reduces late-stage biological risk in cell therapy portfolios.
- Portfolio Impact: Supports risk-adjusted prioritization of regenerative medicine assets.
Implementation Considerations
- Requires expertise in stem cell sourcing, handling, and injection techniques.
- Demands access to wound measurement tools and immunological monitoring infrastructure.
- Necessitates protocol adherence for cross-team reproducibility.
- Adaptable to various ulcer models with attention to immune rejection monitoring.
- Long-term follow-up and laboratory testing are essential for comprehensive safety assessment.
